Lehdistötiedote

AcouSort sell an AcouTrap system to The Hebrew University of Jerusalem.

AcouSort AB today announced the sale of an AcouTrap system to a research group led by Alisa Komsky‑Elbaz, PhD, Assistant Professor at the Hebrew University of Jerusalem.

“The AcouTrap system is especially suitable for the group’s work as they often work with minute samples that are difficult to handle using other technologies, and where the AcouTrap has shown to be particularly well suited to manage their samples,” said AcouSort’s Commercial Director Dr. Agnes Michanek.

Dr. Komsky-Elbaz’s research group at the Hebrew University works within the field of reproductive medicine and studies extracellular vesicles (EVs) and their role in cell‑to‑cell communication, with emphasis on biological processes related to reproduction and early development. AcouSort first met the group in 2020 and visited the university again in 2023. Since then it has been discussed placing of a system at the university.

Revenues generated from the sales of the AcouTrap system is expected to be €38,000.

ABOUT ACOUSORT
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Tapper Partners AB.